SHINE MEDICAL TECHNOLOGIES FILES THE CONSTRUCTION PERMIT APPLICATION WITH NUCLEAR REGULATORY COMMISSION

Published on:

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.

As required by Federal regulations, the Construction Permit application consists of general information about SHINE, an analysis of environmental impacts from the construction and operation of the facility, if any, and a preliminary safety analysis of the planned facility. Today’s filing includes the environmental analysis and general and financial information about SHINE; the remaining portions of the preliminary analysis will be filed in the next several months.

SHINE’s filing begins the NRC’s process of formal acceptance and review, which is expected to

take approximately eighteen months. “This filing is an important milestone as SHINE carries out its plans to construct and operate a facility to produce medical isotopes in Janesville,” said SHINE CEO and founder Greg Piefer. “It represents a lot of hard work by our tem and is a significant step forward for building and operating a facility that will address an important worldwide health care issue.

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.